Common-Size Income Statement
Difficulty: Beginner
Eli Lilly & Co., Common-Size Consolidated Income Statement
| 12 months ended | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| | Revenue | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | |||||
| | Cost of sales | -26.54 | -26.65 | -25.24 | -25.15 | -21.24 | |||||
| | Gross margin | 73.46% | | 73.35% | | 74.76% | | 74.85% | | 78.76% | |
| | Research and development | -23.09 | -24.71 | -24.03 | -24.13 | -23.93 | |||||
| | Marketing, selling, and administrative | -28.81 | -30.40 | -32.73 | -33.75 | -30.83 | |||||
| | Acquired in-process research and development | -4.86 | -0.14 | -2.68 | -1.02 | -0.25 | |||||
| | Asset impairment, restructuring, and other special charges | -7.32 | -1.80 | -1.84 | -2.39 | -0.52 | |||||
| | Operating income | 9.38% | | 16.30% | | 13.47% | | 13.56% | | 23.24% | |
| | Income related to termination of the exenatide collaboration with Amylin | – | – | – | – | 2.14 | |||||
| | Interest expense | -0.98 | -0.87 | -0.81 | -0.76 | -0.69 | |||||
| | Interest income | 0.73 | 0.51 | 0.44 | 0.62 | 0.52 | |||||
| | Venezuela charge | – | -0.96 | – | – | – | |||||
| | Debt extinguishment loss | – | – | -0.84 | – | – | |||||
| | Other income | 0.48 | 0.92 | 1.71 | 1.88 | 0.28 | |||||
| | Other, net, income (expense) | 0.23% | | -0.40% | | 0.50% | | 1.74% | | 2.25% | |
| | Income before income taxes | 9.61% | | 15.90% | | 13.98% | | 15.30% | | 25.48% | |
| | Income taxes | -10.50 | -3.00 | -1.91 | -3.11 | -5.21 | |||||
| | Net income (loss) | -0.89% | | 12.90% | | 12.07% | | 12.19% | | 20.27% | |